Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The hydromorphone protocol is more effective than usual care in Emergency Department (ED) patients age 65 years and older in terms of proportion who choose to forgo additional pain medication within 60 minutes post-baseline in the two groups.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Hydromorphone | Experimental | Hydromorphone protocol |
|
| Usual care | Active Comparator | Usual care |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Hydromorphone | Drug | 0.5 mg IV hydromorphone followed by an optional 0.5 mg IV dose |
|
| Measure | Description | Time Frame |
|---|---|---|
| Number of Patients With Successful Treatment | Number of patients with "successful treatment" is defined as the number of patients who declined additional pain medication within 1 hour of study entry when asked the question, "Do you want more pain medication?". This measure looks at declining pain medication at either 15 minutes or 60 minutes, whereas 4. Post-Hoc refers only to the answer to the question at the 60 minute mark post-baseline. | 1 hour |
| Measure | Description | Time Frame |
|---|---|---|
| Mean Change in Pain Intensity From Baseline to 60 Minutes | Pain intensity is measured on the numerical rating scale (NRS) with scores ranging from 0 ("no pain") to 10 ("worst pain imaginable"). The change in scores over time is calculated by subtracting the score at 60 minutes from the score at baseline (before treatment). These change values were then averaged. | 60 minutes |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Prior use of methadone: the effect of methadone use on the perception of acute pain is unknown and suspected to be altered. The investigators feel that the needs of patients on methadone may exceed the dosage ceiling of 1 mg that will be used for this study. Similar to sickle cell patients and chronic cancer patients, patients on methadone usually require significantly higher doses of opioids to control their pain. Thus, the investigators feel that it would be unethical to restrict the dose that this subset of patients can receive.
Use of other opioids or tramadol within past seven days: to avoid introducing bias related to opioid tolerance that may alter the response to the study medication thereby masking the medication's effect.
Prior adverse reaction to opioids.
Chronic pain syndrome: frequently recurrent or daily pain for at least 3 months results in alteration in pain perception which is thought to be due to down-regulation of pain receptors. Examples of chronic pain syndromes include sickle cell anemia, osteoarthritis, fibromyalgia, migraine, and peripheral neuropathies.
Alcohol intoxication: the presence of alcohol intoxication as judged by the treating physician may alter perception, report, and treatment of pain.
Systolic blood pressure <90 mm Hg: Opioids can produce peripheral vasodilation that may result in orthostatic hypotension.
Oxygen saturation <95% on room air: For this study, oxygen saturation must be 95% or above on room air in order to be enrolled.
Use of monoamine oxidase (MAO) inhibitors in past 30 days: MAO inhibitors have been reported to intensify the effects of at least one opioid drug causing anxiety, confusion and significant respiratory depression or coma.
C02 measurement greater than 46: In accordance with a similar study (04-12-360), three subsets of patients will have their CO2 measured using a handheld capnometer prior to enrollment in the study. If the CO2 measurement is greater than 46, then the patient will be excluded from the study. The 3 subsets are as follows:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Montefiore Emergency Department | The Bronx | New York | 10467 | United States |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 23846749 | Derived | Chang AK, Bijur PE, Davitt M, Gallagher EJ. Randomized clinical trial of an intravenous hydromorphone titration protocol versus usual care for management of acute pain in older emergency department patients. Drugs Aging. 2013 Sep;30(9):747-54. doi: 10.1007/s40266-013-0103-y. |
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Title | Description |
|---|---|---|
| FG000 | Hydromorphone | Hydromorphone protocol Hydromorphone: 0.5 mg IV hydromorphone followed by an optional 0.5 mg IV dose |
| FG001 | Usual Care | Usual care Usual care: Attending administers any IV opioid in any dose he chooses |
| Title | Milestones | Reasons Not Completed | ||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Overall Study |
|
|
Not provided
Not provided
| ID | Title | Description |
|---|---|---|
| BG000 | Hydromorphone | Hydromorphone protocol Hydromorphone: 0.5 mg IV hydromorphone followed by an optional 0.5 mg IV dose |
| BG001 | Usual Care | Usual care Usual care: Attending administers any IV opioid in any dose he chooses |
| Units | Counts |
|---|---|
| Participants |
|
| Title | Description | Population Description | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Denominator Units Selected | Denominators | Classes |
|---|---|---|---|---|---|---|---|---|---|
| Age, Continuous | Mean |
| Type | Title | Description | Population Description | Reporting Status | Anticipated Posting Date | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Time Frame | Units Analyzed | Denominator Units Selected | Arm/Group Information | Denominators | Classes | Analyses | |||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Primary | Number of Patients With Successful Treatment | Number of patients with "successful treatment" is defined as the number of patients who declined additional pain medication within 1 hour of study entry when asked the question, "Do you want more pain medication?". This measure looks at declining pain medication at either 15 minutes or 60 minutes, whereas 4. Post-Hoc refers only to the answer to the question at the 60 minute mark post-baseline. | The discrepancy between the number of patients enrolled and randomized and the number analyzed is due to patient never being given IV opioids (13), enrolled twice (10), and missing primary outcome data (8) | Posted | Count of Participants | Participants | 1 hour |
|
60 minutes
The discrepancy between the number of patients enrolled and randomized and the number analyzed is due to patient never being given IV opioids (13), enrolled twice (10), and missing primary outcome data (8)
Not provided
| ID | Title | Description | Deaths (Affected) | Deaths (At Risk) | Serious Events (Affected) | Serious Events (At Risk) | Other Events (Affected) | Other Events (At Risk) |
|---|---|---|---|---|---|---|---|---|
| EG000 | Hydromorphone | Hydromorphone protocol Hydromorphone: 0.5 mg IV hydromorphone followed by an optional 0.5 mg IV dose |
Not provided
| Term | Organ System | Source Vocabulary | Assessment Type | Notes | Statistical Information |
|---|---|---|---|---|---|
| Oxygen saturation <95% | Respiratory, thoracic and mediastinal disorders |
Not provided
| Title | Organization | Phone | Extension | |
|---|---|---|---|---|
| Andrew Chang, MD, MS | Department of Emergency Medicine, Albert Einstein College of Medicine, Montefiore Medical Center | 718-920-7464 | achang@montefiore.org |
Not provided
| ID | Term |
|---|---|
| D010146 | Pain |
| D004630 | Emergencies |
| ID | Term |
|---|---|
| D009461 | Neurologic Manifestations |
| D012816 | Signs and Symptoms |
| D013568 | Pathological Conditions, Signs and Symptoms |
| D020969 | Disease Attributes |
Not provided
Not provided
| ID | Term |
|---|---|
| D004091 | Hydromorphone |
| ID | Term |
|---|---|
| D009022 | Morphine Derivatives |
| D009019 | Morphinans |
| D053610 | Opiate Alkaloids |
| D000470 | Alkaloids |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Usual care | Drug | Attending administers any IV opioid in any dose he chooses |
|
| Erroneously Enrolled Twice |
|
| BG002 | Total | Total of all reporting groups |
| years |
|
| Sex: Female, Male | Count of Participants | Participants |
|
| Race/Ethnicity, Customized | Count of Participants | Participants |
|
| Region of Enrollment | Count of Participants | Participants |
|
| Weight | Mean | Standard Deviation | lbs |
|
| Diagnosis | Count of Participants | Participants |
|
| Pain Intensity | Pain intensity is measured on the numerical rating scale (NRS), with scores ranging from 0 ("no pain") to 10 ("worst pain imaginable"). | Count of Participants | Participants |
|
| Nauseated or vomited before receiving opioids in the ED | Count of Participants | Participants |
|
| OG001 | Usual Care | Usual care Usual care: Attending administers any IV opioid in any dose he chooses |
|
|
| Secondary | Mean Change in Pain Intensity From Baseline to 60 Minutes | Pain intensity is measured on the numerical rating scale (NRS) with scores ranging from 0 ("no pain") to 10 ("worst pain imaginable"). The change in scores over time is calculated by subtracting the score at 60 minutes from the score at baseline (before treatment). These change values were then averaged. | The discrepancy between the number of patients enrolled and randomized and the number analyzed is due to patient never being given IV opioids (13), enrolled twice (10), and missing primary outcome data (8) | Posted | Mean | Standard Deviation | units on a scale | 60 minutes |
|
|
|
| Post-Hoc | Number of Patients Who Achieved Satisfactory Analgesia at 15 Minutes Post-baseline | Satisfactory Analgesia is defined as declining additional pain medication when asked the question, "Do you want more pain medication?" | The discrepancy between the number of patients enrolled and randomized and the number analyzed is due to patient never being given IV opioids (13), enrolled twice (10), and missing primary outcome data (8) | Posted | Count of Participants | Participants | 15 minutes |
|
|
|
| Post-Hoc | Number of Patients Who Achieved Satisfactory Analgesia at 60 Minutes Post-baseline | "Satisfactory analgesia" is defined as the patient declining additional pain medication when asked the question, "Do you want more pain medication?". This measure refers only to the answer to this question asked at the 60 minute mark. The Primary Outcome (1. Primary Outcome - Number of Patients with successful treatment) refers to the answering "no" to this question at 15 minutes or 60 minutes post-baseline. | The discrepancy between the number of patients enrolled and randomized and the number analyzed is due to patient never being given IV opioids (13), enrolled twice (10), and missing primary outcome data (8) | Posted | Count of Participants | Participants | 60 minutes |
|
|
|
| Post-Hoc | Number of Patients With 50% or Greater Decline in Pain Intensity Score From Baseline to 60 Minutes | Pain intensity is measured on the numerical rating scale (NRS) with scores ranging from 0 ("no pain") to 10 ("worst pain imaginable"). The 50% or greater change in pain score is measured by subtracting the pain score at 60 minutes from the pain score at baseline, then dividing that value by the original baseline value and multiplying by 100% to get a percent change value. | The discrepancy between the number of patients enrolled and randomized and the number analyzed is due to patient never being given IV opioids (13), enrolled twice (10), and missing primary outcome data (8) | Posted | Count of Participants | Participants | 60 minutes |
|
|
|
| Post-Hoc | Number of Patients With a Pain Intensity Score of 3 or Less at 60 Minutes | Pain intensity is measured on the numerical rating scale (NRS) with scores ranging from 0 ("no pain") to 10 ("worst pain imaginable"). | The discrepancy between the number of patients enrolled and randomized and the number analyzed is due to patient never being given IV opioids (13), enrolled twice (10), and missing primary outcome data (8) | Posted | Count of Participants | Participants | 60 minutes |
|
|
|
| Post-Hoc | Pain Intensity Score at 60 Minutes | Pain intensity is measured on the numerical rating scale (NRS) with scores ranging from 0 ("no pain") to 10 ("worst pain imaginable"). | The discrepancy between the number of patients enrolled and randomized and the number analyzed is due to patient never being given IV opioids (13), enrolled twice (10), and missing primary outcome data (8) | Posted | Median | Inter-Quartile Range | units on a scale | 60 minutes |
|
|
|
| 0 |
| 153 |
| 0 |
| 153 |
| 27 |
| 153 |
| EG001 | Usual Care | Usual care Usual care: Attending administers any IV opioid in any dose he chooses | 0 | 166 | 0 | 166 | 32 | 166 |
| Systolic blood pressure <90 mmHg | Vascular disorders |
|
| Pruritus | Skin and subcutaneous tissue disorders |
|
| Nausea | Gastrointestinal disorders | excluding patients who were nauseated or vomiting before receiving initial IV opioids |
|
| Vomiting | Gastrointestinal disorders | excluding patients who were nauseated or vomiting before receiving initial intravenous opioid |
|
Not provided
Not provided
Not provided
| D010335 | Pathologic Processes |
| D006571 |
| Heterocyclic Compounds |
| D006572 | Heterocyclic Compounds, Bridged-Ring |
| D006576 | Heterocyclic Compounds, 4 or More Rings |
| D000072471 | Heterocyclic Compounds, Fused-Ring |
| D010616 | Phenanthrenes |
| D011084 | Polycyclic Aromatic Hydrocarbons |
| D011083 | Polycyclic Compounds |